Purinergic receptors and the inflammatory response mediated by lipids.


Journal

Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133

Informations de publication

Date de publication:
08 2019
Historique:
received: 08 01 2019
revised: 15 02 2019
accepted: 18 02 2019
pubmed: 6 4 2019
medline: 10 7 2020
entrez: 6 4 2019
Statut: ppublish

Résumé

The inflammatory response is regulated by the production of different extracellular mediators, including lipids and extracellular nucleotides. In the extracellular environment, intermediate lipids activate specific G-protein-coupled receptors (GPCRs) in target cells and promote cell recruitment and activation. Extracellular nucleotides activate two types of receptors, the ionotropic purinergic P2X and the metabotropic purinergic P2Y receptors, inducing the release of cytokines and promoting cell recruitment. Several P2X receptors are associated with an increase in the production of immunoactive lipids mediators, which in turn are able to interfere with the activation of different P2Y receptors, establishing a tight signalling link between purinergic receptors and lipid mediators. In this review, we summarise recent studies indicating signalling crosstalk between purinergic P2X and P2Y receptor activation and lipid mediators with a focus on inflammatory diseases. Novel concepts arising from this crosstalk would result in the development of combinatorial therapies targeting lipid synthesis together with individual P2 receptors for the management of inflammatory diseases.

Identifiants

pubmed: 30952060
pii: S1471-4892(18)30136-X
doi: 10.1016/j.coph.2019.02.004
pii:
doi:

Substances chimiques

Lipids 0
Receptors, Purinergic 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-96

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Cristina Alarcón-Vila (C)

Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Malvina Pizzuto (M)

Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Pablo Pelegrín (P)

Instituto Murciano de Investigación Biosanitaria IMIB-Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. Electronic address: pablo.pelegrin@imib.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH